证券代码：301103 证券简称：何氏眼科 公告编号：2025-049 辽宁何氏眼科医院集团股份有限公司 经与会董事审议，作出如下决议： （一）审议通过《关于部分募集资金投资项目延期的议案》 董事会同意公司在募集资金投资项目实施主体、募集资金投资用途及投资规 模均不发生变更的情况下，拟将"沈阳何氏医院扩建项目"达到预定可使用状态日 期延至 2026 年 12 月 31 日、"何氏眼科新设视光中心项目"达到预定可使用状态 日期延至 2027 年 3 月 31 日。 本议案已经公司董事会审计委员会事前审议通过。 保荐机构中原证券股份有限公司对该事项出具了核查意见。 具体内容详见公司同日在巨潮资讯网（http://www.cninfo.com.cn）上披露的 相关公告。 第三届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）第三届董事会第 十五次会议于 2025 年 12 月 25 日在公司会议室以现场及通讯相结合的方式召开， 经全体董事一致同意，本次会议豁免提前 ...

南财智讯12月25日电，何氏眼科公告，公司拟将募集资金投资项目"沈阳何氏医院扩建项目"（计划投资 13,700.00万元）和"何氏眼科新设视光中心项目"（计划投资23,450.00万元）达到预定可使用状态的时间 分别延期至2026年12月31日和2027年3月31日，资金来源为首次公开发行股票募集资金。延期主要由于 公司基于市场环境变化及业务发展需要，审慎控制投资进度，保障项目建设质量与预期效果，导致项目 实施进度放缓。本次延期不涉及项目实施主体、募集资金用途及投资规模的变更，不会对公司主营业务 和整体募资安排造成实质性影响，亦不存在损害股东利益的情形。公司将继续推进募投项目分阶段投 入，并加强动态监管以确保项目高效实施。 ...

Core Viewpoint - He Eye Hospital (301103) is leveraging intelligent systems in ophthalmology, integrating smart algorithms for diagnostic assistance and developing a specialized cloud platform for ophthalmic imaging [1] Group 1: Intelligent Systems and Applications - The company has integrated an intelligent algorithm-assisted diagnostic system and built a specialized ophthalmic imaging cloud platform [1] - A multi-modal data fusion decision system has been developed, generating a 3D digital twin model for eye health [1] - The "He Diabetes Manager" utilizes deep learning algorithms and dynamic blood glucose monitoring devices to provide real-time glucose level tracking and personalized health management for diabetes patients [1] Group 2: Digital Health Management - The company aims to achieve precise glucose control and eye disease prevention for diabetes patients throughout their life cycle [1] - The "Bright House" initiative combines online and offline ophthalmic diagnostic systems, utilizing advanced intelligent diagnostics to identify eye diseases and chronic conditions [1] - The initiative focuses on empowering grassroots eye health management through digital intelligent technology [1] Group 3: Corneal Molding Lens Fitting - In the field of corneal molding lens fitting, the company has established an algorithm model based on intelligent algorithms to enhance fitting efficiency [1] - Current business developments have not significantly impacted the company's main operations or performance [1] - The company will comply with regulatory requirements for information disclosure if there are significant advancements or if disclosure standards are met [1]

Core Viewpoint - He Eye Hospital (301103) has appointed Mr. He Xingru as the new general manager, who will be responsible for the company's daily operations and management [1] Group 1: Company Strategy - The company will adhere to the "Technology and Humanity" philosophy and deepen the "Smart Bright City" strategy [1] - There is a focus on integrating cutting-edge technologies such as digitalization and precision medicine with ophthalmic healthcare [1] - The aim is to establish a comprehensive life-cycle eye health management system [1] Group 2: Long-term Vision - The company believes that a stable long-term market value is derived from solid operational performance and clear value logic [1] - Future strategies will emphasize sustainable development, transparent information disclosure, and effective communication with investors [1] - The company aims to steadily advance its brand building in the capital market and create long-term value for investors [1] Group 3: Future Reporting - Stakeholders are encouraged to pay attention to the company's upcoming periodic reports for specific operational updates [1]

Core Insights - The company is focusing on integrating intelligent systems in ophthalmology, including the development of a smart imaging cloud platform and a multi-modal data fusion decision system, aimed at enhancing health management for diabetes patients and eye disease prevention [1] - The third quarter report for 2025 shows a revenue of 295 million yuan, a year-on-year increase of 5.37%, and a net profit attributable to shareholders of 10.07 million yuan, a significant increase of 230.99% [1] - For the first three quarters of 2025, the company reported a revenue of 855 million yuan, a year-on-year decrease of 1.11%, while the net profit attributable to shareholders was 54.40 million yuan, reflecting a year-on-year increase of 232.18% [2] Group 1 - The company has developed a diabetes management system called "He’s Sugar Manager," which utilizes deep learning algorithms and real-time blood glucose monitoring to provide personalized health management solutions [1] - The "Bright House" initiative combines online and offline ophthalmic diagnostic systems to enhance the detection of eye and chronic diseases through advanced intelligent diagnostics [1] - The company has established an algorithm model for orthokeratology lens fitting based on intelligent algorithms, improving fitting efficiency through deep learning [1] Group 2 - The company has implemented measures to improve the quality and efficiency of medical services, optimize the supply chain, and reduce operational costs, contributing to its financial performance [2] - The focus on high-margin refractive and optometry businesses has been a key strategy in the company's ongoing development [2]

Core Viewpoint - He Eye Hospital (301103) emphasizes its commitment to providing fair access to information for all investors by disclosing shareholder information in regular reports [1] Group 1 - The company will disclose shareholder information at specific reporting periods in its regular reports [1] - For inquiries regarding shareholder numbers at other times, shareholders must provide written proof of their shareholding type and quantity [1] - The company will verify shareholder identity before providing the requested information [1]

Core Viewpoint - He Eye Hospital (301103) has seen a significant increase in financing activities, with a net financing purchase of 128.21 million yuan on December 5, 2025, indicating strong investor interest and confidence in the stock [1][2]. Financing Activities Summary - On December 5, 2025, the financing buy-in amounted to 437.04 million yuan, while financing repayment was 308.83 million yuan, resulting in a net financing purchase of 128.21 million yuan [1]. - The financing balance reached 6864.65 million yuan, with a net financing purchase of 382.06 million yuan over the last three trading days [1]. - In the past 20 trading days, there were 14 days with net financing purchases, reflecting consistent demand for the stock [1]. Daily Financing Data - On December 5, 2025, the net financing purchase was 128.21 million yuan, with a financing balance of 6864.65 million yuan, representing 2.17% of the circulating market value [2]. - The financing balance has shown a steady increase, with a rise of 1.9% on December 5 compared to the previous day [3]. - The financing balance has increased from 6301.00 million yuan on December 1 to 6864.65 million yuan on December 5, indicating a positive trend in investor engagement [2][3].

Group 1 - The company announced the resignation of its General Manager, He Wei, who will focus on his role as Chairman to enhance the company's governance structure and decision-making efficiency [2][3] - He Wei remains a significant shareholder, holding 30,327,379 shares directly and 5,146,921 shares indirectly, and will continue to serve as Chairman and on various committees [3] - The company appointed He Xingru as the new General Manager, effective from the date of the board's approval, to oversee daily operations [4][13] Group 2 - The company held its 14th meeting of the third board on December 5, 2025, where it approved the first grant of restricted stock under the 2025 incentive plan, awarding 5.1 million shares to 240 eligible participants at a price of 13.00 yuan per share [10][17] - The incentive plan aims to enhance employee cohesion and operational efficiency, with performance targets set for the years 2025 to 2027 [23][35] - The plan includes specific conditions for stock vesting, which are tied to the company's performance metrics and individual assessments [24][36]

Core Insights - He Eye Hospital Group has been awarded the "2025 Listed Company ESG Value Transmission Award" and the "2025 Listed Company AI Frontier Innovation Award" at the recent China AI Track and ESG Sustainable Development Conference, recognizing its efforts in ESG value transmission and AI applications in ophthalmology [1][3] Group 1: ESG and Social Responsibility - He Eye Hospital has actively fulfilled its social responsibilities and practiced sustainable development by building a human-centered eye health system through advocacy, capacity building, treatment rehabilitation, charity, and public education [2] - The hospital has trained over 50,000 grassroots doctors and eye health management personnel as a training base for the National Health Commission's blindness prevention and treatment initiatives [2] Group 2: Technological Innovation and Strategy - Under the "Technology Empowering Eye Health" strategy, He Eye Hospital aims to reduce costs, increase efficiency, and expand boundaries by deeply integrating digital transformation with AI technology [2] - The hospital has established an intelligent system covering the entire medical chain, focusing on four core goals: data asset accumulation, service experience enhancement, medical efficiency breakthroughs, and ecological collaboration deepening [2] Group 3: Future Focus and International Cooperation - The company plans to continue focusing on gene therapy, stem cell medicine, and smart healthcare, promoting the deep integration of new technologies like AI with clinical needs [3] - He Eye Hospital aims to enhance its international cooperation and public welfare practices to convey ESG values in the field of eye health [3]

Core Points - He Eye Hospital announced the resignation of its General Manager, He Wei, who will continue to serve as the Chairman of the Board and other committee roles [1] - The Board of Directors has appointed He Xingru as the new General Manager, responsible for daily operations [1] Company Changes - He Wei's resignation is part of a strategy to enhance decentralization and ensure the company's independence [1] - He Xingru's appointment as General Manager is effective immediately following the Board's approval and will last until the current Board's term ends [1]